PARVOVIRUS FORMULATION FOR TREATING TUMORS

• Main Authors: Karsten GELETNEKY, Barbara LEUCHS, Jean ROMMELAERE, Christiane DINSART, Michael DAHM, Ottheinz KREBS
• Format: Patent
• Language: English; Spanish
• Published: 06.07.2018
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Described is a parvovirus formulation which comprises (a) at least 1 x 109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus selected from the group consisting of LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2 x 2 H2O, 50-60 mmol NaC1, 0.9-1.2 mmol KC1, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium.. A preferred use is the therapy of a brain tumour by intratumoral injection. Se describe una formulación de parvovirus que comprende (a) al menos 1 x 109 pfu/mL de parvovirus H1 (H-1PV) o un parvovirus de roedor relacionado, seleccionado del grupo que consiste en LullI, virus minuto del ratón (MMV), parvovirus del ratón (MPV), virus minuto de la rata (RMV), parvovirus de rata o virus de la rata (RV) y (b) un vehí­culo farmacéuticamente aceptable que contiene el 40-50 % de lodixanol (p/v), 0,7-0,9 mmol de CaCI2 x 2 H2O, 50-60 mmol de NaCl, 0,9-1,2 mmol de KCI, 0,7-0,95 mg/mL de Trometamina y 0,05-0,15 mg/mL de Edetato de calcio disódico. Un uso preferido es la terapia de un tumor cerebral por medio de inyección intratumoral.